论文部分内容阅读
目的:分析吉西他滨联合顺铂方案与紫杉醇脂质体联合顺铂方案在治疗晚期非小细胞肺癌中的效果。方法:在本次研究中选择2014年2月到2015年7月来我院接受治疗的35例晚期非小细胞肺癌患者作为研究对象,根据治疗方案差异分为A组和B组,分别给予吉西他滨联合顺铂方案与紫杉醇脂质体联合顺铂方案进行治疗,对治疗效果进行评价。结果:A组和B组的治疗总有效率为76.4%和77.8%,治疗结果无明显差异,不具有统计学意义(p>0.05)。结论:对晚期非小细胞肺癌患者应用吉西他滨联合顺铂方案与紫杉醇脂质体联合顺铂方案其效果无明显差异,均可作为临床治疗方案付诸实践,但使用紫杉醇脂质体副反应更小,故紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌更值得推广和应用。
Objective: To analyze the effect of gemcitabine combined with cisplatin and paclitaxel liposome combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods: In this study, 35 patients with advanced non-small cell lung cancer who were treated in our hospital from February 2014 to July 2015 were selected as study subjects, divided into groups A and B according to the difference of treatment regimens, and were given gemcitabine The combination of cisplatin and paclitaxel liposomes combined with cisplatin treatment, the treatment effect was evaluated. Results: The total effective rates of group A and group B were 76.4% and 77.8%, respectively. There was no significant difference between the two groups (p> 0.05). CONCLUSIONS: There is no significant difference in the efficacy of gemcitabine plus cisplatin versus paclitaxel liposome plus cisplatin in patients with advanced non-small cell lung cancer, both of which can be put into practice as clinical regimens, but the side effects of paclitaxel liposomes are smaller , Paclitaxel liposomes combined with cisplatin in the treatment of advanced non-small cell lung cancer is more worthy of promotion and application.